← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
AntibodystaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+4
임상시험 31상태 RECRUITING
CGTBiologicstaleSyndax Pharmaceuticalscalicheamicin linked to ant…Phase 3

Midostaurin (Midostaurin)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase3#세포유전치료#CAR-T+5
효능 ORR 59.6%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 3

atezolizumab (Tecentriq, Tiragolumab and Atezolizumab)

Head and Neck Neoplasms; MSI-H Cancer · Cancer

#Cancer#Antibody#Phase3#항체#면역항체+5
효능 ORR 77.3%임상시험 31상태 RECRUITING
AntibodystaleRocheVedotin Plus an Anti-CD20 M…Phase 2

Zanubrutinib and Rituximab (Zanubrutinib and Rituximab)

Untreated Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 48.7%임상시험 31상태 RECRUITING
AntibodyQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+5
효능 ORR 27%임상시험 30상태 RECRUITING
ADCBiologicstaleAstraZenecaderuxtecan and rilvegostomi…Phase 2

Rilvegostomig (AZD8205 and AZD2936, AZD8205 and AZD2936 (Rilvegostomig))

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 30상태 RECRUITING
AntibodystaleRochevedotin and anti-CD19 chime…Phase 2

Acalabrutinib combination with Rituximab (Acalabrutinib combination with Rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.4%임상시험 30상태 RECRUITING
AntibodystaleTang-Du Hospitalvedotin (RC48) in combinati…Phase 2

Adebrelimab combined with Apatinib (Adebrelimab combined with Apatinib)

SCLC · SCLC

#SCLC#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 30상태 RECRUITING
CGTBiologicstaleInstituto de Investigación Hosp…Phase 1

Autologous CD19/CD22 CAR T cells (Autologous CD19/CD22 CAR T cells)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 30상태 RECRUITING
AntibodystaleNantes University HospitalPreclinical

Azathioprine + infliximab (Azathioprine + infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Preclinical#항체#면역항체+3
효능 ORR 6%임상시험 30상태 RECRUITING
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib (Defactinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 30상태 RECRUITING
ADCBiologicstaleAstraZenecaApproved

Dexamethasone mouthwash (Dexamethasone mouthwash)

Stomatitis · Stomatitis

#Stomatitis#ADC#Approved#항체약물접합체#antibody-drug-conjugate+1
임상시험 30상태 RECRUITING
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Docetaxel combined + Trastuzumab +Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Docetaxel combined with Trastuzumab±Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 ACTIVE
ADCBiologicstaleHoffmann-La RochePhase 2

Docetaxel or Nab-paclitaxel (Docetaxel or Nab-paclitaxel)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 23.1%임상시험 30상태 RECRUITING
ADCBiologicstaleAmgenPreclinical

Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine)

Anti-CD30; Brentuximab · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 86%임상시험 30상태 ACTIVE
AntibodystaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 DISCONTINUED
ADCBiologicstaleJanssen Research & Development,…Phase 2

Erdafitinib (Erdafitinib)

Muscle Invasive Bladder Urothelial Carcinoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 46.9%임상시험 30상태 RECRUITING
AntibodystaleDanish Headache CenterPreclinical

Erenumab (Erenumab)

Migraine; Migraine Without Aura · Migraine

#Migraine#Antibody#Preclinical#항체#면역항체+3
임상시험 30상태 ACTIVE

31 / 177 페이지

← 이전다음 →